Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company specializing in innovative multispecific antibodies, has announced its participation in Canaccord Genuity's 44th Annual Growth Conference. Bill Lundberg, M.D., President and CEO of Merus, will present on Tuesday, August 13, 2024, from 9:00-9:25 a.m. ET.

The presentation will be webcast live on the Investors page of the Merus website and will remain available for a time after the event. This conference provides Merus with an opportunity to showcase its progress in developing Biclonics® and Triclonics®, their full-length multispecific antibody platforms, to potential investors and industry professionals.

08/06/2024 - 08:00 AM

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at Canaccord Genuity’s 44^th Annual Growth Conference on Tuesday, August 13, 2024 from 9:00-9:25 a.m. ET.

The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, X and LinkedIn.

Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V.

FAQ

When is Merus (MRUS) presenting at Canaccord Genuity's 44th Annual Growth Conference?

Merus (MRUS) is presenting at Canaccord Genuity's 44th Annual Growth Conference on Tuesday, August 13, 2024, from 9:00-9:25 a.m. ET.

Who will be representing Merus (MRUS) at the Canaccord Genuity conference?

Bill Lundberg, M.D., President and Chief Executive Officer of Merus, will be presenting at the Canaccord Genuity conference.

Where can I watch the Merus (MRUS) presentation at the Canaccord Genuity conference?

The presentation will be webcast live on the Investors page of the Merus website. An archived version will also be available there for a time after the event.